Answers are grounded in this paper and cite their sources.
In primary ovarian cancer the combination of HIPEC with interval CRS and neoadjuvant chemotherapy is a safe option that significantly improved 5-year OS and DFS. Its use in other settings should continue to be considered investigational.
No takes yet. Share an insight, caveat, or question.
Filis et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: